Rayner to Upgrade RayPRO+ Digital Health Platform at the ESCRS
Posted on 12/09/2022
12th September 2022. Worthing, United Kingdom. Rayner, the pioneering manufacturer and supplier of ophthalmic solutions for cataract and refractive surgery, today announced the global launch of RayPRO+ at the upcoming ESCRS 2022 congress in Milan.
An evolution of RayPRO: Rayner’s proprietary mobile app and web-based digital platform that proactively collects an insightful blend of Patient Reported Outcomes (PROs) over three years, RayPRO+ has the added ability to record patient outcomes with non-Rayner IOLs (intraocular lenses), creating a richer and more complete picture for surgeons including comparative data.
The strategic importance of RayPRO+
With easy-to-understand reports presented in real-time via the intuitive RayPRO+ dashboard that can be accessed anywhere anytime, RayPRO+ plays a significant role in Rayner’s ambition to become a leader in the digital health sector.
Rayner CEO, Tim Clover, said: “Since launching RayPRO in 2019, we have been closely listening to feedback from surgeons which has resulted in numerous enhancements to the platform. RayPRO+ is by far the biggest evolution to date and has been facilitated by Wolffsohn Research, our software development partner led by Professor James Wolffsohn. I have long believed that decisions within ophthalmology should be based upon large data sets, which is why I’m excited to now offer RayPRO+ to surgeons who are interested in collecting Big Data about their patients’ outcomes, but who may not be current or exclusive users of Rayner IOLs.”
Accompanying the company’s Raytrace online lens calculator, RayPRO+ will become Rayner’s flagship digital solution and signifies a long-term commitment to developing physical and digital solutions that enable surgeons to provide the best outcomes for their patients.
Free RayPRO+ trial during ESCRS
All surgeons who register for RayPRO+ during the ESCRS congress will be given six months free access. RayPRO+ is free for Rayner IOL users and has a £49.99 monthly subscription fee for non-Rayner IOL users.
Surgeons are invited to experience RayPRO+ for themselves by visiting the Rayner booth (C11, Hall 4) at the ESCRS Congress in Milan.
Further product information and downloads can be found at www.staging.rayner.com/RayPRO
Since the implantation of the first Rayner intraocular lens by Sir Harold Ridley 1949, Rayner has continuously pioneered intraocular lens (IOL) design with a goal to improve vision and restore sight worldwide. Today, Rayner’s mission remains to deliver innovative and clinically superior ophthalmic products that respond to the expectations of our global customers to improve the sight and quality of life of their patients.
Headquartered in Worthing, United Kingdom, Rayner markets its medical devices, pharmaceuticals and digital solutions worldwide in over 80 countries through a network of distributors and includes direct sales teams in the United Kingdom, USA, India, Poland, Australia, Germany, Austria, Switzerland, France, Italy, Spain and Portugal.
For further information and media enquiries, please contact Rayner: email@example.com
Not all Rayner products are approved for sale in every country. Please contact your local Rayner distributor for details of which products are available in your area.
©2022 Rayner. EC 2022-203